Janus Henderson Group PLC Sells 4,886,228 Shares of Sotera Health (NASDAQ:SHC)

Janus Henderson Group PLC lessened its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 38.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,782,562 shares of the company's stock after selling 4,886,228 shares during the quarter. Janus Henderson Group PLC owned approximately 2.75% of Sotera Health worth $106,464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of SHC. Two Seas Capital LP boosted its stake in shares of Sotera Health by 624.0% during the 4th quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after acquiring an additional 2,496,136 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of Sotera Health by 140.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company's stock valued at $35,907,000 after buying an additional 1,534,666 shares in the last quarter. Ananym Capital Management LP purchased a new position in shares of Sotera Health during the 4th quarter valued at $13,680,000. Norges Bank purchased a new position in shares of Sotera Health during the 4th quarter valued at $12,764,000. Finally, Walleye Capital LLC lifted its stake in shares of Sotera Health by 818.2% during the 4th quarter. Walleye Capital LLC now owns 775,000 shares of the company's stock valued at $10,602,000 after buying an additional 690,597 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company's stock.

Sotera Health Price Performance

SHC stock traded up $0.06 during mid-day trading on Friday, hitting $12.80. The company had a trading volume of 948,002 shares, compared to its average volume of 1,204,724. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of 51.20 and a beta of 1.88. Sotera Health has a 12-month low of $9.53 and a 12-month high of $17.08. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The company has a 50-day moving average price of $11.57 and a 200 day moving average price of $12.82.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. During the same period in the previous year, the firm posted $0.13 EPS. The business's quarterly revenue was up 2.6% on a year-over-year basis. On average, research analysts anticipate that Sotera Health will post 0.61 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group upgraded shares of Sotera Health from a "neutral" rating to a "buy" rating and lifted their target price for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Barclays lowered their target price on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Piper Sandler decreased their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.80.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.